Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD TrialsErkki Lathouwers, Renato Maserati, Anne Ghys et al.|AIDS Research and Human Retroviruses|2019Cited by 14
P-345. Prevalence of Integrase HIV-1 Drug Resistance Mutations in the United States: 2019-2024Cassidy Henegar, Vani Vannappagari, Kimberley Brown et al.|Open Forum Infectious Diseases|2026Cited by 0